Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
©2020 American Association for Cancer Research..
Agents targeting metabolic pathways form the backbone of standard oncology treatments, though a better understanding of differential metabolic dependencies could instruct more rationale-based therapeutic approaches. We performed a chemical biology screen that revealed a strong enrichment in sensitivity to a novel dihydroorotate dehydrogenase (DHODH) inhibitor, AG-636, in cancer cell lines of hematologic versus solid tumor origin. Differential AG-636 activity translated to the in vivo setting, with complete tumor regression observed in a lymphoma model. Dissection of the relationship between uridine availability and response to AG-636 revealed a divergent ability of lymphoma and solid tumor cell lines to survive and grow in the setting of depleted extracellular uridine and DHODH inhibition. Metabolic characterization paired with unbiased functional genomic and proteomic screens pointed to adaptive mechanisms to cope with nucleotide stress as contributing to response to AG-636. These findings support targeting of DHODH in lymphoma and other hematologic malignancies and suggest combination strategies aimed at interfering with DNA-damage response pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Molecular cancer therapeutics - 19(2020), 12 vom: 20. Dez., Seite 2502-2515 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McDonald, Gabrielle [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.08.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/1535-7163.MCT-20-0550 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316515272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316515272 | ||
| 003 | DE-627 | ||
| 005 | 20231225161245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1535-7163.MCT-20-0550 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316515272 | ||
| 035 | |a (NLM)33082276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McDonald, Gabrielle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2020 American Association for Cancer Research. | ||
| 520 | |a Agents targeting metabolic pathways form the backbone of standard oncology treatments, though a better understanding of differential metabolic dependencies could instruct more rationale-based therapeutic approaches. We performed a chemical biology screen that revealed a strong enrichment in sensitivity to a novel dihydroorotate dehydrogenase (DHODH) inhibitor, AG-636, in cancer cell lines of hematologic versus solid tumor origin. Differential AG-636 activity translated to the in vivo setting, with complete tumor regression observed in a lymphoma model. Dissection of the relationship between uridine availability and response to AG-636 revealed a divergent ability of lymphoma and solid tumor cell lines to survive and grow in the setting of depleted extracellular uridine and DHODH inhibition. Metabolic characterization paired with unbiased functional genomic and proteomic screens pointed to adaptive mechanisms to cope with nucleotide stress as contributing to response to AG-636. These findings support targeting of DHODH in lymphoma and other hematologic malignancies and suggest combination strategies aimed at interfering with DNA-damage response pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Dihydroorotate Dehydrogenase |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Oxidoreductases Acting on CH-CH Group Donors |2 NLM | |
| 650 | 7 | |a EC 1.3.- |2 NLM | |
| 650 | 7 | |a pyrimidine |2 NLM | |
| 650 | 7 | |a K8CXK5Q32L |2 NLM | |
| 700 | 1 | |a Chubukov, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Coco, John |e verfasserin |4 aut | |
| 700 | 1 | |a Truskowski, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Narayanaswamy, Rohini |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Steadman, Mya |e verfasserin |4 aut | |
| 700 | 1 | |a Artin, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Padyana, Anil K |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Ronseaux, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Locuson, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Zi-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Erdmann, Tabea |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Hayes, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Fletcher, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Nellore, Kavitha |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Siva Sanjeeva |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanya, Hosahalli |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, K Satish |e verfasserin |4 aut | |
| 700 | 1 | |a Panigrahi, Sunil K |e verfasserin |4 aut | |
| 700 | 1 | |a Antony, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Gopinath, Sreevalsam |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Zhihua |e verfasserin |4 aut | |
| 700 | 1 | |a Nagaraja, Nelamangala |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Lenny |e verfasserin |4 aut | |
| 700 | 1 | |a Lenz, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Hurov, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Biller, Scott A |e verfasserin |4 aut | |
| 700 | 1 | |a Murtie, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Kevin M |e verfasserin |4 aut | |
| 700 | 1 | |a Ulanet, Danielle B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer therapeutics |d 2001 |g 19(2020), 12 vom: 20. Dez., Seite 2502-2515 |w (DE-627)NLM122520580 |x 1538-8514 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:12 |g day:20 |g month:12 |g pages:2502-2515 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1535-7163.MCT-20-0550 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 12 |b 20 |c 12 |h 2502-2515 | ||